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Abstract
Background: Berberine (BER), the major alkaloidal component of Rhizoma coptidis, has multiple pharmacological
effects including inhibition of acetylcholinesterase, reduction of cholesterol and glucose levels, anti-inflammatory,
neuroprotective and neurotrophic effects. It has also been demonstrated that BER can reduce the production of
beta-amyloid40/42, which plays a critical and primary role in the pathogenesis of Alzheimer’s disease. However, the
mechanism by which it accomplishes this remains unclear.
Results: Here, we report that BER could not only significantly decrease the production of beta-amyloid40/42 and
the expression of beta-secretase (BACE), but was also able to activate the extracellular signal-regulated kinase1/2
(ERK1/2) pathway in a dose- and time-dependent manner in HEK293 cells stably transfected with APP695
containing the Swedish mutation. We also find that U0126, an antagonist of the ERK1/2 pathway, could abolish (1)
the activation activity of BER on the ERK1/2 pathway and (2) the inhibition activity of BER on the production of
beta-amyloid40/42 and the expression of BACE.
Conclusion: Our data indicate that BER decreases the production of beta-amyloid40/42 by inhibiting the expression
of BACE via activation of the ERK1/2 pathway.
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Background
Alzheimer’s disease (AD) is the most prominent form of
senile dementia. In the pathogenesis of AD, amyloid-b
peptide (Ab) plays a critical and primary role [1]. The
aggregation and accumulation of extracellular and intra-
cellular Ab40/42 impairs synaptic plasticity and memory
[2,3]. Ab40/42 is generated by b-secreatase- (beta-site
amyloid precursor protein cleaving enzyme, BACE) and
g-secretase-mediated sequential cleavages of amyloid pre-
cursor protein (APP). Inhibition of the production of
Ab40/42 can be expected to delay the development of AD
[4]. In fact, some nonsteroidal anti-inflammatory drugs
(NSAIDs), including sulindac sulfide, S-ibuprofen, R-ibu-
profen and indomethacin, have been shown to inhibit the
production of Ab40/42 by inhibiting the expression of
BACE and the activity of g-secretase via activating per-
oxisome proliferator-activated receptor g (PPAR g)a n d
inhibiting Rho-Rho associated kinase (Rho-ROCK) path-
way [5,6]. Additionally, some statins, including sinvasta-
tin, rosuvastatin, and lovastatin, the cholesterol-lowering
drugs, have been found to reduce levels of Ab40/42 by
promoting the expression of a-secretase and inhibiting
BACE activity [7-9].
Berberine (BER), an isoquinoline alkaloid existing in
Cortex phellodendri (Huangbai) and Rhizoma coptidis
(Huanglian), has a long history in China as a non-prescrip-
tion drug for the treatment of diarrhea and gastrointestinal
disorders. In recent years, many studies have indicated
that BER has multiple pharmacological effects. BER is a
novel cholesterol-lowering dr u gd i s t i n c tf r o mt h es t a t i n
family. It works by increasing the expression of low-
density lipoprotein receptors (LDLR) and inhibiting lipid
synthesis [10,11]. BER can also improve insulin resistance
and exerts an insulin-independent glucose-lowering effect,
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any medium, provided the original work is properly cited.stimulating insulin secretion and sensitizing insulin activ-
ity, inducing glycolysis, and increasing glucose transport
and uptake activity [12-17]. At the same time, some stu-
dies have found that BER exerts anti-inflammatory effects
by inhibiting arachidonic acid metabolism and the produc-
tion of some inflammatory factors including cyclooxygen-
ase-2 (COX-2), interleukin-1 beta (IL-1b), tumor necrosis
factor-alpha (TNF-a), Interleukin-1 (IL-6) and inductible
nitric oxide synthase (iNOS)[18-23].
BER can pass through the blood-brain barrier and reach
the brain parenchyma in a dose- and time-dependent man-
ner [24], and has multiple neuropharmacological properties
including neuroprotective and neurotrophic effects. It also
stimulates anti-neuronal apoptosis, improves cerebral
microcirculation, reduces depression, and inhibits acetyl-
cholinesterase [25-27]. Notably, one study [28] has reported
that BER can decrease the production of Ab40/42, but the
mechanism remains unclear. Further investigation of how
BER inhibits the expression of BACE may have significant
impact on the treatment of AD. In this study, we therefore
focused on the mechanism of BER on BACE and Ab40/42
inhibition, using HEK293 cells stably transfected with
APP695 containing the Swedish mutation.
Results
Effects of BER and U0126 on the proliferation and
cytotoxicity of HEK293 cells
The MTT assay was used to detect the treatments on the
proliferation of HEK293 cells. Relative to the vehicle
group, no significant declines were observed in the cells
receiving treatments (P > 0.05) (Figure 1A, B and 1C).
The LDH release of cultured medium was used to assay
t h et r e a t m e n t sf o rt h ec y t o t o x i c i t yo fH E K 2 9 3c e l l s .
Compared with vehicle treatment, BER and U0126
showed no significant effects on the release of LDH in
the culture medium (P > 0.05) (Figure 1D, E and 1F), but
3% H2O2 significantly increased the release of LDH in
the culture medium (P < 0.01).
Effects of BER and U0126 on the production of Ab40/42
We assayed the treatments on the extracellular Ab40/42
levels in the medium cultured from HEK293 cells by sand-
wich ELISA. BER (1 μM, 5 μM, 10 μM, and 20 μM) signif-
icantly reduced the levels of Ab40 (366.2 ± 13.5 pg/ml
vehicle control, 131.5 ± 20.8 pg/ml at 1 μM, 56.2 ± 13.5
pg/ml at 5 μM, 54.4 ± 9.2 pg/ml at 10 μM, and 50.8 ± 10.2
pg/ml at 20 μM) for 48 hours of incubation (Figure 2A)
and the levels of Ab42 (152.1 ± 32.9 pg/ml vehicle control,
102.3 ± 5.9 pg/ml at 1 μM, 94.3 ± 3.5 pg/ml at 5 μM, 58.4
±9 . 1p g / m la t1 0μM, and 54.3 ± 10.1 pg/ml at 20 μM)
for 48 hours of incubation (Figure 2D). BER (5 μM) signif-
icantly reduced the levels of Ab40 from 8 hours to 72
hours of incubation (366.2 ± 13.5 pg/ml vehicle control,
131.5 ± 43.8 pg/ml at 8 hours, 58.3 ± 13.4 pg/ml at
24 hours, 56.2 ± 13.5 pg/ml at 48 hours, and 50.8 ± 10.2
p g / m la t7 2h o u r s )( n=5 )( F i g u r e2 B )a n dt h el e v e l so f
Ab42 from 8 hours to 72 hours of incubation (152.1 ± 32.9
pg/ml vehicle control, 82.3 ± 9.1 pg/ml at 8 hours, 62.2 ±
Figure 1 Evaluation of the treatments on the proliferation and the cytotoxicity of HEK293 cells by MTT assay and LDH assay.( A )
Effects of BER (1 μM, 5 μM,10 μM, and 20 μM) on the proliferation of HEK293 for 48 hours of incubation, P > 0.05 compared with vehicle-
treated group (n = 5). (B) Effects of BER (5 μM) on the proliferation of HEK293 for 8, 24, 48, and 72 hours of incubation, P > 0.05 compared with
vehicle-treated group (n = 5). (C). Effects of BER (5 μM), U0126 (0.5 μM), and U0126 with BER (0.5 μM+5 μM) on the proliferation of HEK293 cells
for 48 hours of incubation, P > 0.05 compared with vehicle-treated group (n = 5). (D) Effects of BER (1 μM, 5 μM, 10 μM, and 20 μM) on the
cytotoxicity of HEK293 for 48 hours of incubation, *P < 0.05 when compared with vehicle-treated group (n = 5). (E) Effects of BER (5 μM) on the
cytotoxicity of HEK293 for 8, 24, 48, and 72 hours of incubation, *P < 0.05 when compared with vehicle-treated group (n = 5). (F). Effects of BER
(5 μM), U0126 (0.5 μM), and U0126 with BER (0.5 μM+5 μM) on the cytotoxicity of HEK293 cell for 48 hours of incubation, *P < 0.05 when
compared with vehicle-treated group (n = 5).
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Page 2 of 810.5 pg/ml at 24 hours, 34.5 ± 3.5 pg/ml at 48 hours, and
30.5 ± 10.3 pg/ml at 72 hours) (Figure 2E). U0126 (0.5
μM) was found to significantly alleviate the reduction of
BER (5 μM) on the production of Ab40/42.T h eA b40 levels
of the vehicle, BER (5 μM), U0126 (0.5 μM), and U0126
with BER groups (0.5 μM+5 μM) were 366.2 ± 13.5 pg/ml,
56.2 ± 13.5 pg/ml, 439.2 ± 5.6 pg/ml, and 429.2 ± 11.2 pg/
ml, respectively (Figure 2C). The Ab42 levels of the vehicle,
BER (5 μM), U0126 (0.5 μM), and U0126 with BER
(0.5 μM+5 μM) are 152.1 ± 32.9 pg/ml, 94.3 ± 3.5 pg/ml,
227.94 ± 41.9 pg/ml, and 202.06 ± 18.3 pg/ml, respectively
(Figure 2F).
Effects of BER and U0126 on the expression of BACE
We assayed the expression of BACE in HEK293 cells by
WB. BER (1 μM, 5 μM, 10 μM, and 20 μM) was found to
significantly reduce the expression of BACE for 48 hours
of incubation (Figure 3A). BER (5 μM) was found to signif-
icantly reduce the expression of BACE for 8 hours, 24
hours, 48 hours, and 72 hours of incubation (Figure 3B).
However, U0126 (0.5 μM) was found to significantly
increase the expression of BACE and alleviate the
inhibition of BER (5 μM) on the expression of BACE (Fig-
ure 3C).
Effects of BER and U0126 on the activation of ERK1/2
pathway
We detected the effects of BER on the activation of ERK1/
2 pathway by WB. We found that BER (1 μM, 5 μM, 10
μM, and 20 μM) significantly increased the expression
level of p-ERK1/2 for 48 hours of incubation (Figure 4A).
BER (5 μM) significantly increased the expression level of
p-ERK1/2 for 8 hours, 24 hours, 48 hours, and 72 hours of
incubation (Figure 4B). However, U0126 (0.5 μM) signifi-
cantly inhibited the activation of ERK1/2 and abolished
the activation effect of BER (5 μM) on ERK1/2 for
48 hours of incubation (Figure 4C).
Discussion
In this study, we observed that BER significantly
decreased the production of Ab40/42 and the expression
of BACE via activation of the ERK1/2 pathway in a
dose- and time-dependent manner. We also found that
U0126, an antagonist of ERK1/2 pathway, abolished the
Figure 2 Evaluation of the treatments on the production of Ab4 0 / 4 2i nH E K 2 9 3c e l lb yE L I S A . (A) BER (1 μM, 5 μM, 10 μM, and 20 μM)
can inhibit the production of Ab40 for 48 hours of incubation,*P < 0.01 compared with vehicle-treated group, #P < 0.05 compared with BER (1
μM) groups (n = 5). (B) BER (5 μM) can inhibit the production of Ab40 from 8 to 72 hours of incubation, *P < 0.01 compared with vehicle-
treated group, #P > 0.05 compared with BER (8 h) groups (n = 5). (C) U0126 (0.5 μM) can abolish the inhibition of BER (5 μM) on the production
of Ab40, *P < 0.01 compared with vehicle-treated group, #P < 0.05 compared with vehicle-treated group (n = 5). (D) BER (1 μM, 5 μM, 10 μM,
and 20 μM) can inhibit the production of Ab42 for 48 hours of incubation,*P < 0.01 compared with the vehicle-treated group, #P < 0.05
compared with BER (1 μM and 5 μM) groups (n = 5). (E) BER (5 μM) can inhibit the production of Ab42 from 8 to 72 hours of incubation, *P <
0.01 compared with the vehicle-treated group, #P < 0.05 compared with BER (8- and 24-hour) groups (n = 5). (F) U0126 (0.5 μM) can abolish the
inhibition of BER (5 μM) on the production of Ab42, *P < 0.01 compared with vehicle-treated group, #P < 0.05 compared with vehicle-treated
group (n = 5).
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viously been demonstrated to be able to reduce cancer-
ous conditions by inhibiting the proliferation of tumor
cells [29,30], but we did not find that BER could inhibit
the proliferation and show cytotoxicity toward HEK 293
cells by MTT and LDH assays. From this, it can be con-
cluded that the inhibition of BER on the production of
Ab40/42 is not associated with the anti-proliferative or
cytotoxic qualities of BER.
The enzyme BACE is crucial to the production of
Ab40/42 and the expression of BACE increases in the
brains of AD patients [5]. For this reason, BACE has
been considered as a therapeutic target for AD treat-
ments. On the other hand, the expression and activity of
BACE is regulated by the ERK1/2 pathway in a dose-
and time-dependent manner [31], and BER increases the
expression of LDLR and glucose uptake by activating
the ERK1/2 pathway [10,15]. So berberine-induced
reduction of BACE1 protein levels is related to ERK1
activation. Furthermore, though BER has been shown
unable to inhibit the activity of BACE in vitro [25], the
ERK1/2 pathway negatively modulates BACE1 activity in
Figure 3 Evaluation of the treatments on the expression of BACE by Western blot.( A )B E R( 1μM, 5 μM, 10 μM, and 20 μM) can
significantly decrease the expression of BACE in a dose-dependent manner for 48 hours of incubation, *P < 0.05 compared with vehicle-treated
group, #P < 0.01 compared with vehicle-treated group (n = 3). (B) BER (5 μM) can decrease the expression of BACE from 8 to 72 hours of
incubation, *P < 0.05 compared with vehicle-treated group, #P < 0.01 compared with the vehicle-treated group (n = 3). (C) BER (5 μM) can
decrease the expression of BACE for 48 hours of incubation, U0126 (0.5 μM), and BER with U0126 (5 μM +0.5 μM) can increase the expression of
BACE for 48 hours of incubation, *P < 0.05 compared with vehicle-treated group (n = 3).
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the production of Ab40/42 by inhibit BACE1 activity via
activating ERK1/2 pathway, and it need to be studied in
the next study.
At the same time, BER may decrease the production
of Ab40/42 by affecting the activity of a-secretase and g-
secretase. It has been reported that ERK1/2 is an endo-
genous negative regulator of g-secretase activity, and
NSAIDs can inhibit g-secretase activity by inhibiting the
Rho-ROCK pathway [6,32,33]. BER inhibits tumor cell
migration by inhibiting the Rho-ROCK pathway in
HONE1 cells [34], so it is possible that BER inhibits the
activity of g-secretase by activating the ERK1/2 pathway
and inhibiting the Rho-ROCK pathway. Moreover, BER,
an acetylcholinesterase inhibitor, may be able to upregu-
late a-secretase activity by promoting the translocation
of a-secretase to the cell surface [35]. All these possibili-
ties require further study.
Conclusion
In this study, we demonstrated that BER can decrease
the production of Ab40/42 by inhibiting the expression of
BACE via activation of the ERK1/2 pathway. In previous
studies, we demonstrated that BER improved impaired
spatial memory and increased both the activation of
microglia and the expression of insulin degrading
Figure 4 Evaluation of the treatments on the expression of the activation of ERK1/2 pathway by Western blot. BER (1 μM, 5 μM, 10 μM,
and 20 μM) can significantly increase phosphorylation-ERK1/2 for 48 hours of incubation, *P < 0.05 compared with vehicle-treated group, #P <
0.01 compared with vehicle-treated group (n = 3). (B) BER (5 μM) can increase phosphorylation-ERK1/2 from 8 to 72 hours of incubation, *P <
0.05 compared with vehicle group, #P < 0.01 compared with vehicle-treated group (n = 3). (C) U0126 (0.5 μM) can completely abolish the
activation of BER on ERK1/2, *P < 0.05 compared with the vehicle-treated group, #P < 0.01 compared with vehicle-treated group (n = 3).
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researchers have demonstrated other pharmacological
effects of BER in HEK293 cells, e.g., inhibiting Ab42
aggregation and attenuating the Tau hyperphosphoryla-
tion induced by calyculin A [39,40]. Together, we con-
sider BER to be a very promising drug for use in AD
patients.
Methods
Cell culture and treatments
HEK293 cells stably transfected with APP695 containing
the Swedish mutation were maintained in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with
5% fetal bovine serum and G418 (Sigma, St. Louis, MO,
U.S.) (100 μg / m L )i nah u m i d i f i e da t m o s p h e r ea t3 7 ° C
with 5% CO2. HEK293 cells were given BER (Sigma, St.
Louis, MO, U.S.) (1 μM, 5 μM, 10 μM, and 20 μM),
U0126 (Sigma, St. Louis, MO, U.S.) (0.5 μM), and BER
with U0126 (5 μM+0.5 μM) for 48 hours, and HEK293
cells were also given BER (5 μM) for 8 hours, 24 hours,
48 hours and 72 hours.
MTT analysis
After the cells were treated in the manner described
above, 10 μl of 1 mg/ml MTT stock (Sigma, St. Louis,
MO, U.S.) were added to each well and the incubation
continued for another 4 hours. One hundred microliters
of a solution containing 20% SDS and 50% dimethylfor-
mamide (pH 4.8) were then added to each well. After
overnight incubation, absorption values at a wavelength
of 570 nm were determined by spectrophotometer.
Cellular toxicity analysis
HEK293 cells were plated at a density of approximately
1×1 0
4 cells per well on 24-well plates. After 24 hours of
incubation, the conditioned media were replaced with
new media containing BER, U0126, and BER with U0126
at the final concentrations and the final times indicated.
Lactate dehydrogenase (LDH) activity was determined to
evaluate the cell toxicity of BER, U0126, and BER with
U0126 by using cytotoxicity detection kits (Njjcbio Insti-
tute, China) according to the manufacturer’s instructions.
Hydrogen peroxide (3%) was used as a positive control
and added to the conditioned media during the last hour
of incubation. The baseline was determined in control
wells containing no cells and the values obtained there
were subtracted from those obtained from experimental
wells.
Sandwich ELISA
HEK293 cells were plated at a density of approximately
4×1 0
4 cells per well on 6-well plates. After 24 hours of
incubation, the conditioned media were replaced by new
media containing BER, U0126, and BER with U0126 at
the final concentrations and final times indicated. The
cultured media were harvested and extra cellular Ab
levels were determined by using the Human Ab40/42
Assay Kit (Cusabiao Biotech Co., Ltd., U.S.) according to
the manufacturer’s instructions.
Western blotting (WB) analysis
HEK293 cells were plated at a density of 4 × 10
4 cells per
well on 6-well plates. After 24 hours of incubation, the
conditioned media were replaced by new media contain-
ing BER, U0126, and BER with U0126 at the final con-
centrations and final times indicated. Cells were lysed in
a cell and tissue protein extraction reagent and protease
inhibitor cocktail and phosphotase inhibitor cocktail
(Kangchen Bio-tech, China), phenyl-methyl-sulfonyl-
fluoride-proteomics grade kit (Kangchen Bio-tech,
China). Protein extracts (protein 50 μg) were subjected to
SDS-PAGE. The levels of BACE, p-ERK1/2, ERK1/2, and
GAPDH in the cell lysates were quantified by WB analy-
sis using polyclonal antibody anti-BACE (487-501,
1:10000 dilution, EMD Bioscience, Germany), monoclo-
nal antibody anti-phospho-ERK1/2 and ERK1/2 (137F5
and 197G2, 1:1000 dilution, Cell Signaling Technology,
U.S.), and polyclonal antibody anti-GAPDH (IBN9003L,
1:3000 dilution, KB Biotech, China), respectively. This
was followed by application of peroxidase-conjugated
secondary antibodies (GGHL-15P,1:5000 dilution, ICL
Lab, U.S.). Immunoreactive signals were detected by
enhanced chemiluminescence using ECL Plus WB detec-
tion reagents (Pierce); signal intensity was determined
with a densitometer, LAS-3000 (Fuji Photo Film Co.,
Ltd., Tokyo, Japan). The amounts of immunoreactive
BACE on internal control GAPDH and p-ERK1/2 on
internal control ERK1/2 in each sample were calculated
by using Quality One software (Bio-Red, U.S.).
Statistical analysis
All of the data were expressed as mean ± SD and the
analysis was carried out using the one way analysis of
variance (ANOVA). Values of P <0 . 0 5w e r ec o n s i d e r e d
statistically significant.
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